Louisville, Kentucky, USA, November 17, 2026
US WorldMeds has announced that final results from all cohorts of its Phase II SPEARHEAD-1 clinical trial evaluating TECELRA® (afamitresgene autoleucel) in advanced synovial sarcoma will be presented during a late-breaking oral presentation at the 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting. The meeting is scheduled to take place from November 18 to 21, 2026, in Seoul, South Korea. The presentation will provide comprehensive safety findings and independently reviewed efficacy outcomes from Cohorts 1, 2 and 3, representing the most comprehensive dataset from the registrational trial to date. TECELRA is an important development in cellular immunotherapy because it became the first FDA-approved engineered T-cell therapy for a solid tumor. The upcoming presentation is expected to provide additional insights into its clinical performance in patients with advanced synovial sarcoma, a rare and aggressive soft tissue cancer. The announcement highlights the growing role of engineered T-cell therapies in oncology and the continued investigation of precision-based immunotherapies for cancers with limited treatment options.
Final SPEARHEAD-1 Results to Be Presented at CTOS 2026
The late-breaking presentation will cover clinical findings from all three cohorts of the Phase II SPEARHEAD-1 trial, including safety outcomes and efficacy assessments independently reviewed across the study population. The presentation is titled The SPEARHEAD-1 Trial of Afamitresgene Autoleucel (Afami-cel) in Advanced Synovial Sarcoma: Results of All Cohorts. It has been selected for Session 8, titled Late Breaking Abstracts and Updates – Can They Change Practice? The presentation is scheduled for November 20, 2026, from 11:30 a.m. to 1:00 p.m. Korean Standard Time (KST), with Sandra P. D’Angelo, MD, serving as the presenting author. The trial evaluates afamitresgene autoleucel in patients with advanced synovial sarcoma, focusing on treatment response, clinical outcomes and safety. In addition to the oral presentation, US WorldMeds will present four scientific posters at the conference. These posters will examine factors associated with TECELRA clinical outcomes, comparative effectiveness against other available therapies, engineered T-cell therapies in pediatric synovial sarcoma and first-line treatment research involving letetresgene autoleucel. Together, these presentations demonstrate the company’s continued commitment to advancing cellular immunotherapy research in rare sarcoma populations.
TECELRA Targets MAGE-A4 in Advanced Synovial Sarcoma
TECELRA (afamitresgene autoleucel) is a genetically modified autologous T-cell immunotherapy designed to recognize melanoma-associated antigen A4 (MAGE-A4), a protein expressed in certain cancer cells. The treatment uses a patient’s own T cells, which are collected and genetically modified to express a T-cell receptor capable of recognizing MAGE-A4 in the context of specific human leukocyte antigen (HLA) types. The modified cells are then administered back to the patient to help identify and attack cancer cells expressing the target antigen. TECELRA is FDA-approved for adults and pediatric patients aged 12 years and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, meet specified HLA-A*02 eligibility requirements and have MAGE-A4-positive tumours confirmed through an FDA-approved or cleared companion diagnostic. This precision-based approach is particularly relevant for patients with advanced disease who have limited treatment options following previous chemotherapy. The therapy represents an important advancement in the application of engineered T-cell technology beyond blood cancers and into solid tumour treatment.
Cellular Immunotherapy Advances Rare Cancer Treatment
The upcoming CTOS presentation is expected to contribute important clinical evidence regarding the long-term development and potential application of engineered T-cell therapies in solid tumours. While the announcement confirms that final results from all three SPEARHEAD-1 cohorts will be presented, the complete updated efficacy and safety findings have not yet been disclosed in this announcement. Previously available regulatory data from the combined trial cohorts reported an independently assessed overall response rate of 43.8% among 137 efficacy-evaluable patients, including complete and partial responses. These earlier findings provide clinical context for the upcoming presentation but should not be confused with the new final dataset. TECELRA also carries a boxed warning for serious or life-threatening adverse reactions, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Patients require close monitoring following treatment, including at least seven days of daily monitoring at a healthcare facility after infusion. Meanwhile, letetresgene autoleucel, also known as lete-cel, which will feature in one of the additional conference posters, remains investigational and has not been approved by the FDA or any other regulatory authority. Overall, US WorldMeds’ participation at CTOS 2026 represents an important development in the clinical evaluation of engineered T-cell immunotherapy for rare solid tumours, with the final SPEARHEAD-1 results expected to provide further information about TECELRA’s safety and efficacy in advanced synovial sarcoma.
Source: US WorldMeds press release



